Home › Funds › Patient Square Capital LP › PHVS
Patient Square Capital LP position in PHVS
PHARVARIS N V · Health Care
Patient Square Capital LP reported holding 808,644 shares of PHVS (PHARVARIS N V) in its Q3 2026 13F filing — a position valued at US$25.7M, representing 4.09% of its reported portfolio and ranking #5 among its reported holdings. Patient Square Capital LP has disclosed PHVS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's PHVS position evolved
Patient Square Capital LP first disclosed a stake in PHVS in Q3 2024 at 242,341 shares (US$4.5M). The position peaked in Q3 2026 at 808,644 shares, worth US$25.7M. Across 9 filings, Patient Square Capital LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 808,644 shares valued at US$25.7M — an increase of 137,435 shares quarter over quarter.. Notable position changes include a 41% increase in Q3 2025 (shares rose 11% over the following quarter), a 57% increase in Q4 2025 (shares rose 2% over the following quarter), a 36% increase in Q2 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 242.34K | $4.49M | New |
| Q4 2024 | 207.60K | $3.98M | Reduce |
| Q1 2025 | 245.50K | $3.85M | Add |
| Q2 2025 | 244.28K | $4.30M | Hold |
| Q3 2025 | 345.38K | $8.62M | Add |
| Q4 2025 | 542.70K | $15.06M | Add |
| Q1 2026 | 493.00K | $13.93M | Reduce |
| Q2 2026 | 671.21K | $23.21M | Add |
| Q3 2026 | 808.64K | $25.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- GENERAL ATLANTIC, L.P. 6.55M sh · $226.53M · Q2 2026
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $108.63M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Jones Hill Capital LP 987.64K sh · $31.33M · Q3 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held PHVS?
Patient Square Capital LP has disclosed PHVS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Patient Square Capital LP's current position in PHVS?
As of Q3 2026, Patient Square Capital LP holds 808.64K shares of PHVS (PHARVARIS N V), valued at $25.65M, representing 4.09% of its reported portfolio and ranking #5.
Has Patient Square Capital LP been buying or selling PHVS?
In the latest 13F filing (Q3 2026), Patient Square Capital LP increased its position in PHVS. The position peaked in Q3 2026 at 808.64K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.